People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharmaceuticals, Other, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aravive, Inc. | — | Biotechnology | Series C | $156.1M | $702.9M | 2013 |
| Eyenovia, Inc. | — | Pharmaceuticals | Series C | $66.0M | $312.6M | 2020 |
| Cenerx Biopharma Inc | — | Biotechnology | Series A | $33.3M | $186.3M | 2009 |
| Immusoft Corp | — | Other | Series A | $24.0M | $21.5M | 2018 |
| Neoconix Inc | — | Other Technology | Series A | $17.0M | $25.0M | 2009 |
| Lavante Inc | — | Other Technology | Series A | $16.8M | $105.9M | 2009 |
| Packet Photonics, Inc. | — | Other | Series A | $8.0M | $61.3M | 2013 |
| Bridge Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $2.2M | $83.3M | 2009 |
Anthony Sun at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Anthony Sun on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Johnson | 1 | 12 |
| Srinivas Akkaraju | 1 | 10 |
| Ernest Mario | 1 | 9 |
| Andrew Kau | 1 | 8 |
| Curt LaBelle | 1 | 7 |
| TING PAU OEI | 1 | 7 |
| Keith Krach | 1 | 6 |
| BARRY BUTLER | 1 | 6 |
| T. Peter Thomas | 1 | 6 |
| FRED ESHELMAN | 1 | 5 |
| Steven Goldberg | 1 | 5 |
| Dennis Purcell | 1 | 5 |
| Steven Elms | 1 | 5 |
| MICHAEL DYBBS | 1 | 5 |
| Irwin Federman | 1 | 5 |
| Tsontcho Ianchulev | 1 | 5 |
| Sean Ainsworth | 1 | 5 |
| JEFFREY CLELAND | 1 | 4 |
| Francesco De Rubertis | 1 | 4 |
| Steve Goldberg | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.